Fullerenes versus AIDS
from the go-fullerenes dept.
From PR Newswire on Yahoo comes this news from Toronto: "William Multi-Tech Inc., (“Multi-Tech'') (TSE:WIM – news) announced today that C Sixty Inc. (“C Sixty'') a privately held biotechnology company, in which Multi-Tech has a 40% ownership interest, has begun upscale manufacturing of its lead fullerene based drug candidate for treatment of patients with AIDS and AIDS related disease. As a novel anti-HIV drug, C Sixty's product has to date demonstrated potent activity against multiple strains of the HIV virus including drug resistant and de-novo resistant strains of the virus…The potential for widespread applications of C Sixty's technology in medicine, positions the company as a leader in the emerging field of Nanotechnology and its related Biotechnology market. "



December 26th, 2000 at 12:45 PM
nanomedicine?
A November article in the Houston Chronicle gives more details [search on "c-sixty" at google.com and look for the Houston Chronicle story; select the cached copy]:
Gee, who would have guessed that graphene spheres would have so many miraculous medicinal properties?
Well, maybe it's a bit too soon to tell; according to the article, the company "hopes to begin human testing in the next year." I read somewhere that pharmaceutical companies typically screen about 10,000 compounds for every new drug that makes it to market. It's not unreasonable to hope that the fullerenes or their functionalized derivatives might prove medically useful, but we'll have to wait and see. This is really old-fashioned drug chemistry we're talking about, rather than what we would call nanotechnology.
January 1st, 2001 at 2:26 AM
Reality check necessary
I would agree with the comments that this is more standard drug development rather than nanotechnology per se.
I would also be very concerned with a company that is publishing its results in newspapers rather than peer-reviewed journals.
The articles seem to suggest their products function as protease inhibitors. That implies that their drug candidates function to block the HIV derived enzymes that cleave HIV precursor multi-proteins into individual proteins that perform required functions for HIV replication. It is my impression of chemical structures that protein cleavage blocking agents would be much smaller than the size of typical fullerenes.
As no mechanism is proposed for the activity of these drug candidates, nor peer reviewed verification of the results is cited, I am inclined to be highly dubious of the claims.
November 30th, 2005 at 3:21 PM
This discussion of “Fullerenes versus AIDS” is particularly interesting given the continued advance of the HIV/AIDS pandemic. I am expecially interested in the current state of research since this article appeared. My speficic focus is on assisting emerging organizations as well as community-based organizations in Africa to develop non-traditional approaches to this issues as well as establishing non-traditional parternships that can strengthen the hopes of that affected and infected. That “It’s not unreasonable to hope that the fullerenes or their functionalized derivatives might prove medically useful,…” compeles me to submit this message. Thanks for reading and replying!
December 6th, 2005 at 9:31 PM
this is very good research but still more claws and deffect are observed.the bulky ball is good but it doesnot have potential to cure AIDS ,the replication will still continue